Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03251027 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Intensity-Modulated Stereotactic Radiation Therapy in Treating Patients With Grade II-IV Glioma

StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion dates: Dec 31, 2025 to Dec 31, 2027
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 125 to confirmed 100
    • Site details revised
    v14
  2. Site contact updatedv13
  3. Phase: Phase 2 to Not applicable
    • Primary and study completion dates: Jan 1, 2024 to Dec 31, 2025
    v12
  4. Primary completion date: Jan 1, 2023 to Jan 1, 2024v11
  5. Re-verified, no change to tracked fieldsv10
Show 8 earlier versionsHide 8 earlier versions
  1. Enrollment target: 100 to 125
    • Eligibility criteria revised
    • Secondary endpoints revised (4)
    v9
  2. Primary completion date: Jan 1, 2021 to Jan 1, 2023
    • Study completion date: Jan 1, 2022 to Jan 1, 2024
    v8
  3. Re-verified, no change to tracked fieldsv7
  4. Interventions: Intensity-Modulated Radiation Therapy (Radiation) to Intensity-Modulated Radiation Therapy (Radiation), Quality-of-Life (Other)
    • Secondary endpoints: 1 to 4
    v6
  5. Trial status: Active, Not Recruiting to Recruiting
    • Site details revised
    v5
  6. Enrollment target: 3 to 100
    • Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v4
  7. Eligibility criteria expanded, about 13 wordsv3
  8. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase II trial studies how well intensity-modulated stereotactic radiation therapy works in treating patients with grade II-IV glioma. Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to normal tissue.
Trial Details
NCT Number NCT03251027
Lead Sponsor Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Conditions
(from sponsor)		 Glioblastoma, WHO Grade II Glioma, WHO Grade III Glioma
Related terms Glioblastoma
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov